All In Biotech

Drug Trial Radar · NCT05769010

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

A Prospective, Open-label Explorative Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

Last checked: Nov 20, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Mar 31, 2023

Primary completion

Dec 30, 2028

Study completion Jun 30, 2029

Sponsor

Lead sponsor
Henan Cancer HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Mar 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aimed to evaluate the use of SHR-A1811 in HER2-expression Advanced Breast Cancer patients with brain metastases.

Conditions

  • Metastatic Breast Cancer

Interventions

  • SHR-A1811Drug

    SHR-A1811: intravenous

  • PyrotinibDrug

    Pyrotinib: oral

  • BevacizumabDrug

    Bevacizumab: intravenous

  • AdebelizumabDrug

    Adebelizumab: intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CNS-ORR by investigatorTime frame: 2 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.